Edition:
United States

Calithera Biosciences Inc (CALA.OQ)

CALA.OQ on NASDAQ Stock Exchange Global Select Market

10.27USD
17 Nov 2017
Change (% chg)

$0.47 (+4.85%)
Prev Close
$9.80
Open
$9.90
Day's High
$10.45
Day's Low
$9.90
Volume
263,625
Avg. Vol
129,309
52-wk High
$20.00
52-wk Low
$2.90

Latest Key Developments (Source: Significant Developments)

Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb
Tuesday, 7 Nov 2017 08:01am EST 

Nov 7 (Reuters) - Calithera Biosciences Inc :Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting.Calithera Biosciences Inc - ‍expanding Bristol-Myers Squibb clinical collaboration​.Calithera Biosciences Inc - ‍expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with opdivo​.Calithera Biosciences Inc - ‍analysis of all safety evaluable patients demonstrated CB-839 was well tolerated when combined with opdivo​.Calithera Biosciences - ‍among 16 evaluable melanoma patients, one patient achieved a complete response and two patients achieved partial responses​.Calithera Biosciences Inc - ‍study will be expanded to enroll additional melanoma patients​.Calithera Biosciences Inc - ‍as part of expanded collaboration, melanoma development costs will be shared​.  Full Article

Calithera Biosciences Q3 operating loss per share $0.17
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Calithera Biosciences Inc :Calithera biosciences reports third quarter 2017 financial results and recent highlights.Q3 operating loss per share $0.17.Q3 revenue $7.3 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Q3 revenue view $4.5 million -- Thomson Reuters I/B/E/S.Calithera biosciences inc - ‍as of september 30, 2017, cash, cash equivalents and investments totaled $196.5 million​.Calithera biosciences inc - qtrly ‍research and development expenses were $10.8 million compared with $6.3 million for same period in prior year​.  Full Article

Calithera Biosciences enters into sales agreement with Cowen and Co ‍​
Friday, 18 Aug 2017 04:27pm EDT 

Aug 18 (Reuters) - Calithera Biosciences Inc -:Calithera Biosciences - entered into sales agreement with Cowen And Company, Llc, or Cowen, relating to shares of co's common stock ‍​.Calithera Biosciences says co may offer and sell shares of stock having aggregate offering price of up to $50 million ‍​.  Full Article

Calithera Biosciences files for common stock offering of up to $250 mln
Tuesday, 8 Aug 2017 05:06pm EDT 

Aug 8 (Reuters) - Calithera Biosciences Inc ::Calithera Biosciences Inc files for common stock offering of up to $250 million - SEC filing‍​.  Full Article

Calithera Biosciences reports Q2 operating loss per share $0.15
Tuesday, 8 Aug 2017 04:06pm EDT 

Aug 9 (Reuters) - Calithera Biosciences Inc -:Calithera Biosciences reports second quarter 2017 financial results and recent highlights.Q2 operating loss per share $0.15.Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.Q2 revenue $7.3 million.  Full Article

Calithera Biosciences initiates randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Calithera Biosciences Inc :Calithera Biosciences initiates a randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma.Calithera Biosciences Inc - FDA has granted fast track designation to CB-839.  Full Article

Calithera says FDA fast track designation granted to CB-839
Wednesday, 7 Jun 2017 06:45am EDT 

June 7 (Reuters) - Calithera Biosciences Inc ::Calithera Biosciences announces FDA fast track designation granted to CB-839 for treatment of patients with renal cell carcinoma.Calithera Biosciences - "look forward to initiating a global randomized trial of CB-839 in combination with everolimus for treatment of renal cell carcinoma in second half of 2017".  Full Article

Calithera announces clinical data from product candidate CB-1158
Monday, 5 Jun 2017 06:45am EDT 

June 5 (Reuters) - Calithera Biosciences Inc ::Calithera Biosciences Inc - clinical data from its product candidate CB-1158, a first-in-class arginase inhibitor​.Calithera Biosciences Inc - ‍CB-1158 was generally well tolerated with no drug-related serious adverse events​.Calithera Biosciences Inc - ‍no grade 3 treatment related adverse events were reported.​.  Full Article

Bristol-Myers Squibb, Calithera Biosciences expand collaboration
Wednesday, 10 May 2017 06:59am EDT 

May 10 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb and Calithera Biosciences expand collaboration evaluating opdivo (nivolumab) in combination with CB-839 into non-small cell lung cancer and melanoma.Calithera Biosciences Inc - study to evaluate potential of CB-839 plus opdivo to target immunosuppressive cancer metabolism in tumor microenvironment.  Full Article

Calithera Biosciences reports Q1 operating loss $0.22/shr
Tuesday, 9 May 2017 04:06pm EDT 

May 9 (Reuters) - Calithera Biosciences Inc :Calithera Biosciences reports first quarter 2017 financial results and recent highlights.Q1 operating loss per share $0.22.Q1 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Q1 revenue $4.2 million.Q1 revenue view $17.6 million -- Thomson Reuters I/B/E/S.Calithera Biosciences Inc expects that its cash, cash equivalents and investments will be between $180 and $190 million at end of 2017.  Full Article

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting